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Abstract
Objective
To define the current treatment practice of Guillain-Barre´ syndrome (GBS).
Methods
The study was based on prospective observational data from the first 1,300 patients included in
the International GBS Outcome Study. We described the treatment practice of GBS in general,
and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment,
(3) treatment-related fluctuations, (4) mild forms (able to walk independently), and (5) variant
forms including Miller Fisher syndrome, taking patient characteristics and hospital type into
account.
Results
We excluded 88 (7%) patients because of missing data, protocol violation, or alternative
diagnosis. Patients from Bangladesh (n = 189, 15%) were described separately because 83%
were not treated. IV immunoglobulin (IVIg), plasma exchange (PE), or other immunotherapy
was provided in 941 (92%) of the remaining 1,023 patients, including patients with severe GBS
(724/743, 97%), mild GBS (126/168, 75%), Miller Fisher syndrome (53/70, 76%), and other
variants (33/40, 83%). Of 235 (32%) patients who did not improve after their initial treatment,
82 (35%) received a second immune modulatory treatment. A treatment-related fluctuation
was observed in 53 (5%) of 1,023 patients, of whom 36 (68%) were re-treated with IVIg or PE.
Conclusions
In current practice, patients with mild and variant forms of GBS, or with treatment-related
fluctuations and treatment failures, are frequently treated, even in absence of trial data to
support this choice. The variability in treatment practice can be explained in part by the lack of
evidence and guidelines for effective treatment in these situations.
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Plasma exchange (PE) and IV immunoglobulin (IVIg) are the
only proven effective treatments for Guillain-Barre´ syndrome
(GBS), although there has been little formal exploration of
optimal dosage and treatment duration for either.1,2 The
implementation of these treatments in clinical practice is
complicated by the variability in disease presentation and se-
verity. Most therapeutic trials with PE or IVIg focused on adult
patients who were unable to walk independently.1–3 At present,
it is unclear whether these treatments are also effective in
children, patients with mild GBS, or clinical variants including
Miller Fisher syndrome (MFS).4,5 It is also unknown if treat-
ment is still effective when administered at a later stage of the
disease. Furthermore, it is not uncommon that patients con-
tinue to deteriorate or demonstrate poor recovery after initial
treatment.6 In some patients, there can be subsequent de-
terioration after initial stabilization or recovery, a phenomenon
referred to as treatment-related fluctuation (TRF).6 To date,
there has been a paucity of studies describing the effects of
treatment in these clinical scenarios. In the absence of adequate
evidence and consensus on treatment guidelines, dilemmas
continue to exist in the treatment of GBS.7 Such dilemmas may
result in substantial variation in the current treatment of GBS.
The aim of this study was to define the variation in current
treatment practice of GBS and to identify factors that may
contribute to this variation. This in turn will allow us to identify
areas of variation, develop new clinical trials to address these,
and initiate the development of treatment guidelines.
Methods
Study design
Data were collected from the International GBS Outcome
Study (IGOS), an ongoing, prospective, observational cohort
study.8 Patients were included from 154 hospitals (106 [69%]
university hospitals, including university-affiliated teaching
hospitals, and 48 [31%] non-university hospitals) in 19 coun-
tries. All patients were included within 2 weeks from onset,
independent of age, disease severity, GBS variant, or treatment.
Standard protocol approvals, registrations,
and patient consents
IGOS received approval from the institutional review boards
from individual participating centers and written informed
consent was obtained from all patients.
Patient groups
The study was based on the first 1,300 inclusions in IGOS
(May 2012–January 2017). We described the type, regimen,
and timing of immunotherapy. The treatment practice was
related to the country of residence, clinical variant (sensori-
motor, pure motor, MFS, and other variants), disease severity,
and electrophysiologic subtype (demyelinating vs axonal
GBS). We also compared the treatment practice in children
(younger than 18 years at diagnosis) to that in adults. Patients
from Bangladesh, who rarely received immunotherapy for
GBS, were excluded from further analyses.9–11
In addition, we described treatment practice in the following
specific clinical scenarios: (1) severe GBS, (2) severe GBS
with no clinical recovery after initial treatment, (3) GBS with
TRF, (4) mild GBS, and (5) GBS variants including MFS.
Severe GBS was defined as being unable to walk in-
dependently at nadir (GBS disability score ≥3) and mild GBS
as being able to walk independently at nadir (GBS disability
score <3).12 Initial failure of clinical recovery was defined as
worsening or failure to improve by at least one grade on the
GBS disability scale from nadir to week 4 (or not improving
from the first to the second week in case of a missed visit at
week 4). The presence of a TRF was determined by the
treating physician. Electrophysiologic subtypes were defined
by the first nerve conduction study based on local reference
values and the Hadden et al.13 criteria.
Data collection
We collected data on demographics (age, sex, country of
residence) and clinical characteristics including disease se-
verity (GBS disability score, limb weakness, sensory deficits,
facial, bulbar, and oculomotor weakness, pain, and auto-
nomic dysfunction) at entry and 1, 2, and 4 weeks follow-up.
Documentation of autonomic dysfunction was left to the
discretion of the treating physician and was defined as car-
diac, blood pressure, gastro-enteric, bladder, pupil, or other
autonomic dysfunction. Limb muscle strength was recorded
by the Medical Research Council (MRC) sum score, ranging
from 60 (full muscle strength) to 0 (total paralysis).14 The
disability caused by GBS was defined by the highest GBS
disability score in the first 4 weeks after study entry (nadir),
ranging from 0 (healthy) to 6 (dead).15 When assessing
treatment practice in patients without clinical recovery or
with GBS-TRF, second-line treatment that was provided as
part of a clinical trial (e.g., Second Immunoglobulin Dose in
GBS trial [SID-GBS]16 and Inhibition of Complement Ac-
tivation in GBS trial [ICA-GBS]17) was not taken into ac-
count. Disease severity during a TRF was defined by the GBS
disability score and MRC sum score. When a TRF occurred
between 2 consecutive study visits, the data recorded at the
Glossary
GBS = Guillain-Barre´ syndrome; IGOS = International GBS Outcome Study; IQR = interquartile range; IVIg = IV
immunoglobulin; MFS = Miller Fisher syndrome; MP = methylprednisolone; MRC = Medical Research Council; PCB =
pharyngeal-cervical-brachial weakness; PE = plasma exchange; RCT = randomized controlled trial; SID-GBS = Second
Immunoglobulin Dose in GBS trial; TRF = treatment-related fluctuation.
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first visit after the TRF were used to determine severity of
symptoms.
Statistical analysis
We analyzed the data using SPSS Statistics version 24 (SPSS
Inc., Chicago, IL). Continuous data were presented as
medians with interquartile ranges (IQR) and were compared
with Mann-Whitney U test. Categorical data were presented
as proportions with percentages and were compared with χ2
or Fisher exact tests. A 2-sided p value <0.05 was considered
significant.
Data availability statement
Data collected in IGOS will be used initially for planned re-
search projects conducted by the IGOS Consortium. Some
data will be made available from the corresponding author,
upon reasonable request. The data are not publicly available
because they contain information that could compromise the
privacy of our patients.
Results
Study cohort
From the IGOS 1,300 cohort, we excluded 71 (5%) patients
who had an alternative diagnosis, 6 (0.5%) due to protocol
violation, and 11 (0.8%) due to insufficient data (figure 1).
The remaining 1,212 (93%) patients originated from the
following continents: Europe n = 664 (55%), Asia n = 277
(23%), North and South America n = 238 (20%), Africa n =
25 (2%), and Australia n = 8 (1%). Most of these patients
were included by university hospitals (n = 978, 81%). In the
Asian group, 189 patients were from Bangladesh. The ma-
jority of Bangladeshi patients were not able to walk in-
dependently at nadir (n = 174, 92%), but 144 (83%) of these
severely affected patients did not receive immunotherapy. Of
the remaining 30 patients who did receive immunotherapy, 16
(9%) received PE, 12 (7%) IVIg, 1 (1%) small volume PE, and
1 (1%) dexamethasone monotherapy. Since the treatment
practice in the Bangladesh cohort deviated strongly from that
of other countries, these patients were excluded from further
analyses, leaving the Asian group with 88 patients.
Initial treatment
Of the remaining study cohort of 1,023 patients, 941 (92%)
received immunomodulatory treatment. Most patients were
initially treated with IVIg (n = 862, 84%), which was started
within a median of 4 days after the onset of symptoms (IQR
2–7). IVIg was initiated after 2 weeks in 18 (2%) patients, and
after 4 weeks in 5 (1%) patients. A total IVIg dosage of 2 g/kg
body weight was given in 5 days in 754 (87%) patients, in 2
days in 61 (7%) patients, in 3–4 days in 36 (4%) patients, and
in 6–7 days in 8 (1%) patients. Two patients received 2.5 g/kg
in 5 days. In 36 (4%) of the 1,001 administered IVIg courses,
methylprednisolone (MP) was used as add-on treatment.
Sixty-seven patients (7%) were initially treated with PE within
a median of 6 days (IQR 3–9) after onset of symptoms. Most
patients underwent 5 PE sessions (n = 47, 70%). Others
received 2 sessions (n = 2, 3%), 3 sessions (n = 2, 3%), 4
sessions (n = 9, 13%), 6 sessions (n = 6, 9%), or 7 sessions
(n = 1, 1%). The PE sessions were performed during a median
of 8 days (IQR 6–9, range 2–16).
Eight (1%) patients were initially treated with other treat-
ments, such as monotherapy with corticosteroids (n = 5) or
immunoadsorption (n = 3). Of the 5 patients initially treated
with corticosteroids only, one received an additional course of
IVIg, and one received 2 additional courses of IVIg with MP
add-on.
The remaining 86 (8%) patients in the study cohort received
no immunotherapy. Fifty-seven (66%) of these patients had
mild GBS, and 22 (26%) had MFS or another local variant
(sensory ataxic GBS, n = 6; pharyngeal-cervical-brachial var-
iant, n = 1).
Treatment of severe GBS
There were 743 (81%) patients with severe GBS who were
unable to walk independently at nadir (figure 1). In the ma-
jority of countries, these patients were treated with IVIg
(57%–100%) (figure 2). PE was seldom administered (about
4%) except in Malaysia (33%), Italy (30%), and the United
States (15%). Immunoadsorption was applied only in Ger-
many, where it was administered in 3 (8%) of the 36 severely
affected patients. There were no differences in the type of
initial treatment (IVIg, PE, or other) in severely affected
patients with sensorimotor GBS vs the pure motor variant, or
between demyelinating and axonal subtypes of GBS. How-
ever, patients with the axonal subtype (n = 16/42, 38%) were
more often treated with multiple courses than patients with
the demyelinating subtype (n = 49/296, 17%; p = 0.001).
Axonal GBS was associated with more severe limb weakness
(indicated by lower MRC sum score) during the first 4 weeks
as compared to demyelinating GBS.
Treatment of patients not improving after initial
treatment
In 235 (32%) of the 743 severely affected patients, we ob-
served no initial clinical improvement on the GBS disability
scale from nadir to 4 weeks (excluding patients with a TRF). A
second immunotherapy was instituted in 82 (35%) of these
patients, most often in the Americas (n = 26/55, 47%),
compared to Europe (n = 50/159, 31%, p = 0.04) and Asia
(n = 6/15, 40%, p = 0.77) (table). The proportion of patients
who received a second immunotherapy did not differ between
university (n = 59/179, 33%) and non-university hospitals
(n = 23/56, 41%, p = 0.27). Of the 211 IVIg-treated patients
without initial clinical improvement, 73 (35%) received ad-
ditional immunotherapy. Most patients received a second
course of IVIg (n = 48, 66%), which was started at median 12
days (IQR 8–17) after completing the first IVIg course. In
other IVIg-treated patients, the treating physician switched to
PE (n = 22, 30%), which was started within 2 weeks after
completing IVIg in 17 (77%) of the 22 patients (median 6
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days, IQR 3–13). Three other IVIg-treated patients received
other forms of immunotherapy. Twenty-three (11%) of 211
IVIg-treated patients received a third, fourth, or fifth immu-
notherapy (figure 3).
Of the 17 PE-treated patients not showing clinical recovery in
the first 4 weeks, 8 (47%) received additional immunother-
apy. In 7 (41%) of these, the treating physician switched to
IVIg after a median time of 2 days (IQR 1–4) after completing
PE. One (6%) patient was re-treated with a second round of
PE sessions. Three (18%) of 17 PE-treated patients received
a third immunotherapy (figure 3).
Treatment of TRFs
A TRF occurred in 53 (5%) of 1,023 patients included in this
study (figure 1). TRFs occurred at a median of 23 days (IQR
16–31) after the start of initial treatment. Of the 50 patients
initially treated with IVIg, 31 (62%) were re-treated with IVIg
for their TRF. In 4 (8%) other patients, the physician
switched treatment from IVIg to PE. Of the 3 patients initially
treated with PE, one was retreated with IVIg. The remaining
17 (32%) patients received no treatment for their TRF. In
patients who were re-treated for their TRF, the TRF occurred
at an earlier time point than in untreated patients (median
time to TRF after start of initial treatment [IQR]: treated 21
days [14–27], untreated 32 days [25–54], p = 0.008). In
addition, a higher proportion of treated patients was unable to
walk independently around the time of the TRF (treated n =
33/36 [92%], untreated n = 10/17 [59%]; p = 0.008), and the
MRC sum score was lower (median MRC sum score [IQR]:
treated 41 [18–51], untreated 49 [43–60]; p = 0.019). Finally,
patients admitted to a university hospital were more often re-
Figure 1 Patient and study cohort
Nonresponderwas defined asworsening or failure to improveby at least one gradeon theGuillain-Barre´ syndrome (GBS) disability scale fromnadir toweek 4
(or not improving from the first to the second week in case of a missed visit at week 4).27 Other GBS variants = pharyngeal-cervical-brachial, sensory ataxic,
Bickerstaff brainstem encephalitis, and bilateral facial weakness. GBS DS = GBS disability score; IGOS = International GBS Outcome Study; MFS =Miller Fisher
syndrome; TRF = treatment related fluctuation.
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treated for their TRF (n = 31/39, 80%) than those admitted
to a non-university hospital (n = 5/14, 36%, p = 0.01).
Treatment of mild GBS
Of the cohort of 913 patients with limb weakness, 168 (18%)
had a mild form of GBS and were still able to walk in-
dependently at nadir. In this group of patients, 126 (75%)
were treated with immunotherapy, being either IVIg in 121
(72%) or PE in 5 (3%) patients. The remaining 42 (25%)
received no immunotherapy. The proportion of mildly af-
fected patients receiving immunotherapy varied among
countries, and was highest in the Americas (82%), followed by
Asia (75%) and Europe (74%, table) (Americas vs Europe p =
0.32, Americas vs Asia p = 0.68). The subgroup of patients
with mild GBS receiving immunotherapy more often had
autonomic dysfunction in the first 4 weeks from study entry
(n = 29/126, 23%) compared to those with mild GBS not
receiving immunotherapy (n = 2/42, 5%, p = 0.01). The most
frequently reported autonomic symptoms were blood pres-
sure fluctuations (n = 14/126, 11%), gastro-enteric dysfunc-
tion (n = 10/126, 8%), bladder dysfunction (n = 9/126, 7%),
and cardiac dysfunction (n = 8/126, 6%). The treated vs the
untreated patients with mild GBS did not differ with respect
to age, sex, MRC sum score, GBS disability score, cranial
nerve dysfunction, sensory deficits, ataxia, or pain during the
first 4 weeks after study entry. There was no difference in
treatment provided by university (n = 97/132, 74%) vs non-
university hospitals (n = 29/36, 81%, p = 0.39).
Treatment of MFS and other variants
In the study cohort, 70 (7%) patients had MFS, and 40 (4%)
patients had another distinct variant form of GBS. The patients
with MFS were treated with IVIg (n = 49, 70%), PE (n = 2,
3%), or other immunotherapy (n = 2, 3%), and 17 (24%)
received no treatment. In Europe (n = 33/38, 87%) and
America (n = 13/18, 72%), more patients with MFS received
immunotherapy than in Asia, where 6 out of 11 (55%) of the
MFS patients were treated (Europe vs Asia p = 0.03, America
vs Asia p = 0.43). The subgroup of treated MFS patients
slightly more often reported pain during the first 4 weeks (n =
26/53, 49%) than the untreated patients (n = 4/17, 24%, p =
0.064). The decision to treat a patient with MFS was not
associated with the clinical phenotype or type of hospital. The
rare variants of GBS included sensory ataxic GBS (n = 24),
pharyngeal cervical brachial variant (n = 13), Bickerstaff
brainstem encephalitis (n = 2), and bilateral facial weakness
(n = 1). Thirty patients (75%; 15 sensory ataxic, 12
pharyngeal-cervical-brachial weakness [PCB], 2 Bickerstaff
Figure 2 Country-specific initial treatment of severely affected patients with Guillain-Barre´ syndrome (GBS)
This figure contains data from countries that have included at least 10 patients in the International GBS Outcome Study (IGOS). IVIg = IV immunoglobulin; PE =
plasma exchange.
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brainstem encephalitis, and 1 bilateral facial weakness) were
treated with IVIg, 3 (8%; all sensory ataxic) with PE, and 7
(18%; 6 sensory ataxic, 1 PCB) received no therapy.
Treatment of children
There were 60 (6%) children aged below 18 years (median 4
years, IQR 2–12), of whom 53 (90%) were unable to walk
independently at nadir. Five (8%) were not treated with im-
munotherapy; they all had mild GBS. All others received IVIg.
Children were similarly treated in university and non-university
hospitals. Compared to adults, children were more often
treated with a 2-day IVIg regimen (children n = 30/54, 56% vs
adults n = 31/775, 4%) than a 5-day regimen (children n = 24/
54, 44% vs adults n = 744/775, 96%, p < 0.001). A considerable
subgroup of children (n = 23) came from Argentina, who were
all treated with IVIg 2 g/kg in 2 days.
Discussion
This study demonstrates a considerable variation in the cur-
rent treatment practice of patients with GBS. Our study
showed that in high-income countries, nearly all patients with
severe GBS received initial treatment with IVIg or PE. In
patients without clinical improvement, about one-third re-
ceived a second treatment. Patients developing a secondary
deterioration after initial stabilization or improvement (TRF)
were retreated in only two-thirds of cases. Patients with
a milder form of GBS who were still able to walk in-
dependently were treated with IVIg or PE in 75% of cases. A
similar proportion of patients with MFS or other (local)
variants received this immunotherapy. The observed variation
in treatment of GBS is in part explained by the lack of ther-
apeutic trials that have investigated treatment efficacy in these
specific clinical situations.
IVIg was the first choice of treatment in 92% of treated GBS
patients. Most patients received the recommended dosage of
2 g/kg body weight in 5 days, but some received a 2-day
regimen. Children were more frequently treated with the
latter scheme, presumably because this is better tolerated in
young children. The optimal regimen of IVIg for GBS is
currently undefined, but a randomized controlled trial (RCT)
comparing a 5- and 2-day regimen in children indicated that
a 2-day regimen is equally effective, but is more frequently
followed by a TRF.18 Methylprednisolone was provided as
Table Regional differences in treatment of subgroups of patients with Guillain-Barre´ syndrome (GBS)
Clinical situation and treatment Full cohort (n = 1,023) Europe (n = 664) America (n = 238) Asiaa (n = 88)
Severe GBS n = 743 n = 485 n = 177 n = 57
IVIg 662 (89) 442 (91) 152 (86) 46 (81)
PE 56 (8) 27 (6) 20 (11) 9 (16)
Other 6 (1) 5 (1) 0 (0) 0 (0)
None 19 (3) 11 (2) 5 (3) 2 (4)
Nonimproving n = 235 n = 159 n = 55 n = 15
Second immunotherapyb 82 (35) 50 (31) 26 (47) 6 (40)
TRF n = 53 n = 45 n = 7 n = 0
Second immunotherapy2,b 36 (68) 31 (69) 5 (71) na
Mild GBS n = 168 n = 112 n = 39 n = 12
IVIg 121 (72) 80 (71) 31 (79) 8 (67)
PE 5 (3) 3 (3) 1 (3) 1 (8)
None 42 (25) 29 (26) 7 (18) 3 (25)
MFS n = 70 n = 38 n = 18 n = 11
IVIg 49 (70) 30 (79) 12 (67) 6 (55)
PE 2 (3) 1 (3) 1 (6) 0 (0)
Other 2 (3) 2 (5) 0 (0) 0 (0)
None 17 (24) 5 (13) 5 (28) 5 (46)
Abbreviations: IVIg = IV immunoglobulin; MFS = Miller Fisher syndrome; PE = plasma exchange; TRF = treatment-related fluctuation.
Values are n (%).
a Asia not including Bangladesh.
b Consisting of IVIg, PE, or corticosteroids alone.
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add-on treatment in only 4% of the total number of admin-
istered IVIg courses. A single RCT indicated a short-term
effect of MP as add-on to IVIg after correction for known
prognostic factors, but showed no difference in improvement
on the GBS disability scale.7,19 PE was provided as initial
treatment in 7% of treated patients, and the proportion of PE-
treated patients depended on the country of origin. PE is
considered equally effective to IVIg for GBS, and the local
preference may depend upon presence of contraindications to
IVIg, the availability of resources, health care insurance, or
protocols.1–3,20,21 The number of sessions and duration of
treatment with PE varied between patients. One trial in-
vestigated the optimal number of PE sessions and found that 4
sessions were better than 2, but equally effective to 6 sessions
in relation to time to walk with aid and time on a ventilator.12
Immunoadsorption was instituted only in Germany, where 2
immunoadsorption trials were conducted. This may explain
why the use was limited to German centers, in addition to
reimbursement differences and costs.22,23 Some patients were
treated with corticosteroids only, even though this treatment
is considered ineffective for GBS.24 The treatment practice in
high-income countries is in marked contrast with the situation
in Bangladesh, where only 15% of patients with severe GBS
received immunotherapy. Most inhabitants of Bangladesh
cannot afford treatment with either IVIg or PE.9,10 Low-cost
alternative treatments for GBS are required and small volume
plasma exchange is currently under investigation.25
Multiple treatment courses were administered in patients
without improvement after initial treatment. In severely af-
fected patients who did not improve after a first treatment
with IVIg or PE, 35% received a second treatment, 11% a third
treatment, and some even a fourth and a fifth treatment.
Patients who received multiple courses of treatment more
often had axonal GBS, which in the IGOS cohort is associated
with more severe limb weakness, and could have influenced
the decision to repeat treatment.11 The efficacy of a second
course of IVIg is yet unknown, but is currently investigated in
SID-GBS trial.16 In some of these patients initially treated
with IVIg, the treating physician switched to PE, which was
often started within 2 weeks of completion of IVIg. While the
efficacy of this treatment practice is unproven, one may argue
that IVIg and PE have different therapeutic targets and that if
one treatment fails, the other might still be effective. A con-
sequence of this early secondary treatment with PE is that
IVIg is washed out and cannot further contribute to the re-
covery.7 Other patients were treated with PE followed by
IVIg. Previously, an RCT comparing PE or IVIg alone to PE
Figure 3 Treatment of patients with a severe form of Guillain-Barre´ syndrome (GBS) not responding to initial treatment
Treatment of 235 patients with a severe form of GBS who showed no improvement after initial treatment. ICA-GBS = Inhibition of Complement Activation in
GBS trial; IVIg = IV immunoglobulins; MP = methylprednisolone; PE = plasma exchange; SID-GBS = Second Immunoglobulin Dose in GBS trial.
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followed by IVIg showed no difference in outcome.20 This
trial was not designed to address IVIg treatment efficacy in
patients not responding to PE.
Another group of patients receiving secondary treatments were
those with a TRF. Previous studies have shown that TRFs may
occur in up to 12% of GBS patients.11 In the current study,
TRFs were reported in 53 (5%) patients, of whom 68% were
re-treated with IVIg or PE. A higher proportion of re-treated
TRF patients was unable to walk independently and the treated
group had more severe limb weakness around the time of the
TRF, which indicates that the decision to start treatment in case
of a TRFmay depend on the severity of symptoms. In addition,
re-treatment for a TRF was more often provided in university
vs non-university hospitals. No trials have investigated the ef-
ficacy of treatment of a TRF in patients with GBS. The ratio-
nale for re-treatment of TRFs is that these likely result from
a transient effect of the first treatment in a patient with ongoing
disease activity.3,7 Yet 32% of patients with a TRF in the study
cohort received no additional treatment.
Although the treatment efficacy of IVIg and PE was largely
demonstrated in patients with GBS unable to walk, our study
showed that in current clinical practice, 75% of patients with
mild disability were also treated. One RCT demonstrated that
in patients with mild GBS, 2 sessions of PE shortened the time
to onset of motor recovery and hospital discharge compared
to supportive care only.12Moreover, more than three-quarters
of patients with MFS and other variants of GBS were treated
with IVIg or PE, despite the fact that treatment efficacy has
not been demonstrated for these subgroups and the prognosis
of MFS in general is considered to be good independent of
treatment.26 In our study cohort, patients with MFS had
a higher chance of receiving immunotherapy in Europe and
America compared to Asia. The decision to start treatment
may have been prompted by the higher frequency of auto-
nomic dysfunction in patients with mild GBS, and pain in
patients with MFS. No other differences were found between
the treated and untreated patients with mild GBS and MFS.
The decision to treat may have been influenced by the ex-
pertise of the treating clinician and the policy in the local
hospitals. University hospitals were overrepresented in the
IGOS Consortium, although the treatment practice did not
differ from non-university hospitals except in the situation of
a TRF. In addition, clinicians with a special interest in GBS are
likely overrepresented. This may have resulted in an un-
derestimation of the variation in treatment practice because of
their expertise, or in an overestimation because of the access
to multiple treatment options in tertiary reference centers. We
were not able to assess the effect of expertise and years of
clinical experience on treatment practice, because this in-
formation was not collected in IGOS. Another limitation of
the study was that while the IGOS aims to include the full
spectrum of GBS and variants, the included patient pop-
ulation may be biased, especially towards more severe cases.
In addition, data were collected in IGOS at standard time
points, and changes between visits that may have prompted
the decision to start treatment are possibly unobserved. This
limitation could also have influenced the number of TRFs,
which is relatively low compared to other studies. Further-
more, data on the GBS treatment practice in regions and
countries not represented in IGOS are lacking.
The treatment practice currently provided for GBS varies be-
tween patients, especially with respect to initial treatment of
mild and variant forms, and retreatment of TRF and non-
responding patients. Such treatment could be beneficial in terms
of clinical outcome and cost-effectiveness, but selective treat-
ment trials are lacking and complicated because of the rarity and
diversity of GBS. Whether such evidence can be generated by
comparative treatment studies based on observational data
needs to be determined. Further studies are required to develop
evidence-based guidelines on the treatment of GBS.
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